Tofacitinib attenuates IL-6-mediated endothelial tissue factor induction in vitro without affecting platelet aggregation in vivo: mechanistic insights into cardiovascular risk in rheumatoid arthritis
Despite clinical concerns raised by ORAL Surveillance, our findings indicate no direct enhancement of platelet reactivity by TOFA. Instead, TOFA attenuated IL-6-driven TF expression in endothelial cells, pointing to a possible protective effect on vascular thrombogenic pathways. Further studies are warranted to reconcile these in vitro observations with real-world data on CV outcomes in RA.
Authors
- Mariarosaria Morello (ORCID: https://orcid.org/0009-0003-7690-0347)
- Daniele Mauro (ORCID: https://orcid.org/0000-0002-9022-8863)
- Alessia Salzillo
- I. Pantano
- Daniela Iacono (ORCID: https://orcid.org/0000-0003-3679-2305)
- Plinio Cirillo (ORCID: https://orcid.org/0000-0001-7818-4952)
- F. Ciccia
- Maura Raimondi
- Flavia Riccio
- Gisella Titolo (ORCID: https://orcid.org/0009-0002-7146-7823)
- Giulio Forte (ORCID: https://orcid.org/0009-0000-6218-9185)
- Gennaro De Rosa
Institutions
- Federico II University Hospital (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- University of Naples Federico II (IT)
Publication Details
- Journal
- Clinical and Experimental Rheumatology
- Published
- 2025-03-04
- DOI
- https://doi.org/10.55563/clinexprheumatol/k0fdes
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00